Zeinab Tavakkol Afshari1, Amin Reza Nikpoor1,2, Jalil Tavakkol Afshari1,2, Rashin Ganjali1, Parvaneh Sanglakh Ghoochan Atigh3, Fatemeh Homaei Shandiz4, Khadijeh Jamialahmadi5,6. 1. Immunogenetic and Cell Culture Department, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Allergy and Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Biochemistry Department, Mashhad Payame Noor University, Mashhad, Iran. 4. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Breast cancer is one of the most common cancers among women worldwide. Tumor protein 53 (TP53) and its regulator, the mouse double murine 2 (MDM2) protein homologue, influence tumorigenesis through their key roles in cell division and response to DNA damage. The MDM2 SNP309T>G (rs2279744) polymorphism in the promoter region of the MDM2 can cause dysfunction and inactivation of TP53, which promotes tumor progression. The aim of this study was to investigate the possible association between this polymorphism and breast cancer in a northeastern Iranian population. METHODS: A case-control study with 128 female breast cancer patients and 143 healthy women was conducted. PCR-ARMS was performed to assess the MDM2 SNP309T>G (rs2279744) polymorphism. RESULTS: No significant association was found between the GG genotype or G allele polymorphisms and breast cancer in patients or controls (p = 0.116, OR [95% CI]: 1.267 [0.616, 2.603] and p= 0.143, OR [95% CI]: 1.326 [0.908, 1.935], respectively). For the G allele polymorphism, a significant difference of 8 years in the average cancer diagnosis age was observed between TT and TG carriers (40.57 vs. 48.15 years, respectively, p = 0.029). CONCLUSION: The SNP309T>G polymorphism in MDM2 may not be associated with breast cancer in this Iranian population.
BACKGROUND:Breast cancer is one of the most common cancers among women worldwide. Tumor protein 53 (TP53) and its regulator, the mouse double murine 2 (MDM2) protein homologue, influence tumorigenesis through their key roles in cell division and response to DNA damage. The MDM2 SNP309T>G (rs2279744) polymorphism in the promoter region of the MDM2 can cause dysfunction and inactivation of TP53, which promotes tumor progression. The aim of this study was to investigate the possible association between this polymorphism and breast cancer in a northeastern Iranian population. METHODS: A case-control study with 128 female breast cancerpatients and 143 healthy women was conducted. PCR-ARMS was performed to assess the MDM2 SNP309T>G (rs2279744) polymorphism. RESULTS: No significant association was found between the GG genotype or G allele polymorphisms and breast cancer in patients or controls (p = 0.116, OR [95% CI]: 1.267 [0.616, 2.603] and p= 0.143, OR [95% CI]: 1.326 [0.908, 1.935], respectively). For the G allele polymorphism, a significant difference of 8 years in the average cancer diagnosis age was observed between TT and TG carriers (40.57 vs. 48.15 years, respectively, p = 0.029). CONCLUSION: The SNP309T>G polymorphism in MDM2 may not be associated with breast cancer in this Iranian population.
Authors: Wenwei Hu; Zhaohui Feng; Lan Ma; John Wagner; J Jeremy Rice; Gustavo Stolovitzky; Arnold J Levine Journal: Cancer Res Date: 2007-03-15 Impact factor: 12.701
Authors: C E Bueso-Ramos; T Manshouri; M A Haidar; Y Yang; P McCown; N Ordonez; A Glassman; N Sneige; M Albitar Journal: Breast Cancer Res Treat Date: 1996 Impact factor: 4.872
Authors: Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701
Authors: M Batori; M Ruggieri; E Chatelou; A Straniero; G Mariotta; L Palombi; G Casella; M Basile; M C Casella Journal: Eur Rev Med Pharmacol Sci Date: 2006 Mar-Apr Impact factor: 3.507
Authors: Jinyun Chen; Donghui Li; Ann M Killary; Subrata Sen; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier Journal: Ann Surg Oncol Date: 2008-11-20 Impact factor: 5.344
Authors: Ellen R Copson; Helen E White; Jeremy P Blaydes; David O Robinson; Peter W Johnson; Diana M Eccles Journal: BMC Cancer Date: 2006-03-24 Impact factor: 4.430